Upgrade to SI Premium - Free Trial

Barclays on Teva Pharma (TEVA) Amid 1.5pct Drop: '<$30 as a buy-the-dip oppty'

March 19, 2026 12:33 PM
Barclays analyst Glen Santangelo reiterated an Overweight rating and $38.00 price target on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments